Filing Flows › Longeveron (LGVN) › Q3 2025
Longeveron (LGVN) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Longeveron (LGVN) reported revenue of $137K for the third quarter 2025 (Q3 2025), -82% from a year earlier and -57% from the quarter before.
Longeveron, Q3 2025: revenue $137K (-82% year over year), net loss $7.2M, operating cash flow −$5.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $137K | -57% | -82% |
| Operating profit | −$7.3M | — | — |
| Net earnings | −$7.2M | — | — |
| Operating cash flow | −$5.1M | — | — |
What changed
Revenue was $137K in Q3 2025, down 82% year over year and down 57% from the previous quarter. Clinical Trial Revenue was the largest line at 69% of revenue. Contract Manufacturing Revenue lost $340K year over year (down 90%), 53% of the total change.
Gross margin was 91.2%, up 3.0 points from a year earlier. Operating costs exceeded revenue by $7.3M, an operating margin of -5335.8%. Operating expenses grew 39% against a revenue fall of 82%. The fastest-growing cost line was Research & development (+75%). The quarter ended with a net loss of $7.2M, wider than the previous quarter's $5.0M loss.
Operating cash flow was −$5.1M. Non-cash charges added back $264K of depreciation and amortization and $448K of share-based compensation. Working capital and other items added $1.5M. Capital expenditures of $57K exceeded it, leaving free cash flow of −$5.1M.
Questions
What was Longeveron's revenue in the third quarter 2025?
Longeveron (LGVN) reported revenue of $137K for the third quarter 2025 (Q3 2025), -82% from a year earlier and -57% from the quarter before.
Source: Longeveron 10-Q on SEC EDGAR.